Daily Ards Research Analysis
Analyzed 5 papers and selected 3 impactful papers.
Summary
Analyzed 5 papers and selected 3 impactful articles.
Selected Articles
1. Sugammadex versus neostigmine for reversal of neuromuscular blockade and postoperative pulmonary complications (SNaPP): an international, randomised, controlled, phase 4 trial.
A large, masked, multicentre RCT (n=3498) showed sugammadex modestly reduced the composite of postoperative pulmonary complications or death compared with neostigmine (19.0% vs 21.5%; RR 0.88; p=0.049), primarily driven by a reduction in atelectasis. No increase in treatment-related adverse events was observed.
Impact: This is the largest pragmatic trial comparing sugammadex and neostigmine for neuromuscular blockade reversal with blinded outcome assessment; results directly inform perioperative drug choice and guidelines.
Clinical Implications: Consider using sugammadex as first-line reversal for aminosteroid neuromuscular blockade in adults undergoing major abdominal or thoracic surgery to modestly reduce postoperative pulmonary complications, particularly atelectasis; cost and availability should be balanced against small absolute risk reduction.
Key Findings
- Sugammadex reduced postoperative pulmonary complications or death (19.0% vs 21.5%; RR 0.88; p=0.049).
- Reduction was mainly in atelectasis (18.4% vs 21.1%; RR 0.86; p=0.030).
- No significant differences observed in pneumonia, aspiration, or mortality; no treatment-related adverse events identified.
Methodological Strengths
- Large, pragmatic, multicentre randomized design with masking of outcome assessors and adjudication committee.
- Intention-to-treat analysis and pre-registered protocol with clinically meaningful composite primary outcome.
Limitations
- Absolute risk reduction was small; clinical significance of reduced atelectasis is uncertain.
- Dosing was at clinicians' discretion, introducing heterogeneity in administered doses.
Future Directions: Cost-effectiveness analyses, subgroup assessments (e.g., high-risk pulmonary patients), and real-world implementation studies to inform guideline updates.
BACKGROUND: Sugammadex and neostigmine are used to reverse aminosteroid neuromuscular-blocking drugs at the end of surgery. We aimed to determine whether reversal of neuromuscular blockade with sugammadex reduces the incidence of postoperative pulmonary complications or death compared with neostigmine.
METHODS: We conducted a pragmatic, international, multicentre, randomised, controlled, phase 4 trial involving 44 hospitals in Australia, Aotearoa New Zealand, and Hong Kong. Eligible patients were adults (aged ≥40 years) who were having abdominal or thoracic surgery under general anaesthesia and lasting at least 2 h, with an expected postoperative hospital stay of 1 night or longer. Patients were randomly assigned (1:1) to sugammadex or neostigmine, administered intravenously in doses chosen by the attending anaesthesiologist, for reversal of rocuronium-induced or vecuronium-induced neuromuscular blockade at the end of surgery. Randomisation was done via a web-based service, in random permuted blocks of varying sizes of 2 and 4 and stratified by centre. Patients, research staff who were responsible for outcome assessments, and members of the endpoint adjudication committee were masked to group assignment. The primary outcome was postoperative pulmonary complications or death up to hospital discharge (or postoperative day 7 if still in hospital). The trial is registered with the Australian New Zealand Clinical Trials Registry (ACTRN12623000394640) and is closed to accrual.
FINDINGS: Patients were recruited between July 21, 2023, and July 3, 2025; 3498 patients were included in the intention-to-treat population (1745 [49·9%] in the sugammadex group and 1753 [50·1%] in the neostigmine group). Postoperative pulmonary complications or death occurred in 331 (19·0%) of 1743 patients in the sugammadex group and 377 (21·5%) of 1752 patients in the neostigmine group (risk ratio [RR] 0·88 [95% CI 0·77-1·00]; p=0·049). Death occurred in one (0·1%) and two (0·1%) patients (RR 0·50 [95% CI 0·05-5·53]; p >0·99), atelectasis in 320 (18·4%) of 1742 patients and 370 (21·1%) of 1750 patients (0·86 [0·76-0·99]; p=0·030), pneumonia in 37 (2·1%) of 1742 patients and 38 (2·2%) of 1750 patients (0·98 [0·62-1·53]; p=0·92), and pulmonary aspiration in four (0·2%) of 1742 and seven (0·4%) of 1750 patients (0·57 [0·17-1·96]; p=0·38) in the sugammadex and neostigmine groups, respectively. Acute respiratory distress syndrome was not reported. No adverse events were deemed to be treatment related.
INTERPRETATION: Sugammadex reduced the incidence of postoperative pulmonary complications or death compared with neostigmine. The risk reduction was small with atelectasis of uncertain clinical significance being the most common complication. Sugammadex can be considered as a first-line drug for reversal of aminosteroid-induced neuromuscular blockade at the end of surgery.
FUNDING: Australian Medical Research Future Fund and the Hong Kong Health and Medical Research Fund.
2. Association between mechanical ventilation duration and maternal-neonatal factors in critically ill neonates: A retrospective study.
Retrospective analysis of 319 ventilated neonates found median total ventilation 133.0 h; invasive ventilation median 48.0 h; 83.7% required subsequent non-invasive support. Ventilation duration negatively correlated with gestational age and birth weight, indicating these neonatal factors primarily determine ventilation length across RDS and non-RDS subgroups.
Impact: Identifies perinatal determinants (gestational age, birth weight) of ventilation duration in a contemporary NICU cohort, supporting risk-stratified respiratory management and resource planning.
Clinical Implications: Use gestational age and birth weight as primary risk indicators when planning respiratory support duration and weaning strategies in critically ill neonates; tailor ventilatory approaches and anticipate need for extended non-invasive support in more premature or low-birth-weight infants.
Key Findings
- Median total mechanical ventilation duration was 133.0 hours (IQR 146.0); invasive median 48.0 hours (IQR 58.0).
- 83.7% of infants required non-invasive ventilation following invasive support.
- Ventilation duration was negatively correlated with gestational age and birth weight across RDS and non-RDS subgroups.
Methodological Strengths
- Relatively large NICU cohort (n=319) with detailed perinatal and initial physiological data.
- Subgroup analyses comparing RDS and non-RDS provided disorder-specific insight.
Limitations
- Retrospective single-center design with potential for residual confounding and selection bias.
- Abstract truncated—detailed multivariate adjustment, effect sizes, and P-values not fully available in provided text.
Future Directions: Prospective multicentre studies to validate predictive models incorporating gestational age, birth weight, and other perinatal factors; interventional trials testing tailored ventilatory protocols by risk strata.
OBJECTIVE: To examine the associations between neonatal-maternal characteristics and mechanical ventilation duration in critically ill neonates, and to explore differences between respiratory distress syndrome (RDS) and non-RDS subgroups. METHODS: This retrospective study included 319 neonates who required mechanical ventilation in the neonatal intensive care unit of our hospital between 1 January 2022 and 31 December 2024. Data on neonatal demographics, Apgar scores, initial arterial blood gas parameters and maternal characteristics, including age, delivery mode and comorbidities, were collected. The primary outcome was total ventilation duration. Correlation and subgroup analyses were performed. RESULTS: The median duration of total mechanical ventilation (invasive + non-invasive) was 133.0 (interquartile range (IQR): 146.0) h. All neonates received invasive mechanical ventilation with a median duration of 48.0 (IQR: 58.0) h, and 83.7% subsequently required non-invasive ventilation support. Ventilation duration was negatively correlated with gestational age ( CONCLUSIONS: Neonatal factors, especially gestational age and birth weight, critically impact ventilation duration in critically ill neonates. Tailored respiratory management addressing diagnosis and key perinatal factors (gestational age, birth weight) may improve outcomes.
3. Successful treatment by high dose glucocorticoid of miliary tuberculosis complicated with acute respiratory distress syndrome: a case report.
A single-case report of miliary tuberculosis with ARDS in a previously healthy 25-year-old: diagnosis confirmed by biopsy; anti-TB therapy started after liver recovery. High-dose methylprednisolone (160 mg/day) plus NIPPV produced initial improvement but led to barotrauma (pneumothorax, subcutaneous/mediastinal emphysema) requiring discontinuation and surgical drainage. With continued anti-TB treatment and supportive care, the patient fully recovered at 1 year.
Impact: Although a single case, it documents a successful integrated approach (high-dose steroids + NIPPV + anti-TB therapy) for miliary TB with ARDS and highlights the real risk of ventilator-associated barotrauma, informing clinicians facing similar rare, high-mortality scenarios.
Clinical Implications: In severe miliary TB with ARDS, adjunctive high-dose glucocorticoids may stabilize inflammation and oxygenation while anti-TB therapy is instituted, but noninvasive ventilation can cause barotrauma; close monitoring and readiness to manage pneumothorax/DIC are essential. This supports cautious, case-by-case steroid use and ventilatory strategy planning.
Key Findings
- Diagnosis of miliary tuberculosis with ARDS was confirmed by percutaneous lung biopsy despite negative sputum smears.
- High-dose methylprednisolone (160 mg/day) combined with NIPPV produced clinical and radiological improvement but was complicated by pneumothorax, subcutaneous and mediastinal emphysema, and suspected DIC.
- After discontinuation of NIPPV, drainage and supportive therapy with continued anti-TB treatment and glucocorticoids, the patient made a complete recovery at 1 year.
Methodological Strengths
- Detailed clinical timeline with imaging, biochemical, microbiologic, and histopathologic confirmation of diagnosis.
- Longitudinal follow-up (1 year) demonstrating durable recovery.
Limitations
- Single case report—limited generalizability and no control for steroid or ventilation strategy effects.
- Potential publication bias for successful outcome; cannot establish causality or optimal steroid dosing/timing.
Future Directions: Collect case series or cohort data on steroid use, timing, and ventilatory strategies in tuberculosis-associated ARDS; consider registry-based studies to assess risks of barotrauma with NIPPV in infectious ARDS.
A 25-year-old previously healthy man presented with a productive cough for 2 months and progressive dyspnea for 1 week. He did not respond to initial anti-infective treatment at a local hospital. Chest computed tomography (CT) demonstrated diffuse miliary nodules, ground-glass opacities throughout both lungs, and bilateral pleural effusion (more prominent on the right). Laboratory tests revealed type I respiratory failure, elevated inflammatory markers, hyponatremia, hypoproteinemia, and raised tumor markers (NSE, CYFRA21-1, SCC, CA125). Sputum acid-fast bacilli smears were negative, but pleural fluid analysis showed elevated adenosine deaminase and interferon-gamma, suggestive of tuberculous pleurisy. Percutaneous lung biopsy confirmed epithelioid granulomas with positive acid-fast staining, establishing the diagnosis of miliary tuberculosis, tuberculous pleurisy, severe pulmonary infection, and acute respiratory distress syndrome (ARDS). Anti-tuberculosis therapy was withheld initially due to elevated liver enzymes and was initiated once liver function normalized. High-dose methylprednisolone (160 mg/day) combined with noninvasive positive pressure ventilation (NIPPV) was added, yielding initial improvement. However, complications arose after 8 days of NIPPV, including pneumothorax, subcutaneous and mediastinal emphysema, and suspected disseminated intravascular coagulation (DIC). NIPPV was discontinued, subcutaneous incision and xiphoid puncture drainage performed, and supportive measures (cryoprecipitate, immunoglobulin, continued glucocorticoids) instituted. Symptoms and imaging gradually resolved. After 1 year of anti-tuberculosis treatment, the patient achieved complete clinical and radiological recovery. This case highlights that, alongside potent anti-tuberculosis therapy, high-dose glucocorticoids combined with NIPPV (with cautious management of barotrauma risks) can effectively control life-threatening miliary tuberculosis complicated by ARDS.